title: The coming of age of molecular tumor profiling.
abstract: While adjuvant chemotherapy has been shown to modestly improve survival for patients with resected non-small cell lung cancer (NSCLC), the morbidities associated with administration of these drugs are substantial. The identification of molecular profiles that may predict a patient's need for adjuvant therapy may prove highly useful. In a recently published article, Zhu et al identify a 15-gene signature that serves as an independent prognostic marker for early-stage NSCLC, stratifying patients into low- and high-risk groups. Further, the authors found that the gene signature has predictive utility in determining the potential benefit of adjuvant chemotherapy.
authors.affiliation: Division of Thoracic and Foregut Surgery, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
authors.forename: Mara B
authors.initials: MB
authors.lastname: Antonoff
authors.forename: Jonathan
authors.initials: J
authors.lastname: D'Cunha
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D020869:Gene Expression Profiling / Q000379:methods; D005820:Genetic Testing; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000601:surgery; D058990:Molecular Targeted Therapy; D018579:Patient Selection; D011237:Predictive Value of Tests; D011379:Prognosis